

院長の研究業績・論文リスト

(※IFとはインパクトファクターの略であり、高値ほどその学術雑誌の評価（質）が高いことを示します)

I 原著 (英文)

1. Tsutsumi Y, Tanaka J, Kanamori H, Musashi M, Minami H, **Fukushima A**, Yamato H, Ehira N, Kawamura T, Obara S, Ogura N, Asaka M, Imamura M, Masauzi N.: Effectiveness of propagermanium treatment in multiple myeloma patients. [Eur J Haematol. 73\(6\), 397-401, 2004](#) (IF=2.653)
2. Tsutsumi Y, Kanamori H, Minami H, Musashi M, **Fukushima A**, Ehira N, Yamato H, Obara S, Ogura N, Tanaka J, Asaka M, Imamura M, Masauzi N.: Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine. [Ann Hematol.84\(4\), 269-71, 2005](#) (IF=3.083)
3. Tsutsumi Y, Tanaka J, Minami H, Musashi M, **Fukushima A**, Ehira N, Kanamori H, Yamato H, Sasaki J, Funaki C, Hasegawa S, Obara S, Ogura N, Asaka M, Imamura M, Masauzi N.: Acute biphenotypic leukemia and an acquired X chromosome. [Cancer Genet Cytogenet. 157\(1\), 94-5, 2005](#). (IF=1.536)
4. Sobirin MA, Kinugawa S, Takahashi M, **Fukushima A**, Homma T, Ono T, Hirabayashi K, Suga T, Azalia P, Takada S, Taniguchi M, Nakayama T, Ishimori N, Iwabuchi K, Tsutsui H.: Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. [Circ Res. 111\(8\), 1037-47, 2012](#) (IF=11.972)
5. Takada S, Kinugawa S, Hirabayashi K, Suga T, Yokota T, Takahashi M, **Fukushima A**, Homma T, Ono T, Sobirin MA, Masaki Y, Mizushima W, Kadoguchi T, Okita K, Tsutsui H.: Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. [J Appl Physiol \(1985\). 114\(7\), 844-57, 2013](#) (IF=3.519)
6. **Fukushima A**, Kinugawa S, Homma T, Masaki Y, Furihata T, Abe T, Suga T, Takada S, Kadoguchi T, Okita K, Matsushima S, Tsutsui H.: Increased plasma soluble (pro)renin receptor levels are correlated with renal dysfunction in patients with heart failure. [Int J Cardiol. 168\(4\), 4313-4, 2013](#) (IF=4.852)
7. Homma T, Kinugawa S, Takahashi M, Sobirin MA, Saito A, **Fukushima A**, Suga T, Takada S, Kadoguchi T, Masaki Y, Furihata T, Taniguchi M, Nakayama T, Ishimori N, Iwabuchi K, Tsutsui H.: Activation of invariant natural killer T cells by α -galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice. [J Mol Cell Cardiol. 62, 179-88, 2013](#) (IF=5.130)
8. **Fukushima A**, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Abe T, Suga T, Takada S, Kadoguchi T, Katsuyama R, Oba K, Okita K, Tsutsui H.: Decreased serum brain-derived neurotrophic factor levels are correlated with exercise intolerance in patients with heart failure. [Int J Cardiol.168\(5\), e142-4, 2013](#) (IF=4.852)
9. Suga T, Kinugawa S, Takada S, Kadoguchi T, **Fukushima A**, Homma T, Masaki Y, Furihata T, Takahashi M, Sobirin MA, Ono T, Hirabayashi K, Yokota T, Tanaka S, Okita K, Tsutsui H.: Combination of exercise training and diet restriction normalizes limited exercise capacity and impaired skeletal muscle function in diet-induced diabetic mice. [Endocrinology. 155\(1\), 68-80, 2014](#) (IF=4.438)
10. Takada S, Hirabayashi K, Kinugawa S, Yokota T, Matsushima S, Suga T, Kadoguchi T, **Fukushima A**, Homma T, Mizushima W, Masaki Y, Furihata T, Katsuyama R, Okita K, Tsutsui H. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. [Eur J Pharmacol. 740, 690-6, 2014](#) (IF=2.730)

11. Hamaguchi S, Kinugawa S, Matsushima S, **Fukushima A**, Yokota T, Sakakibara M, Yokoshiki H, Tsuchihashi-Makaya M, Tsutsui H; JCARE-CARD Investigators. Clinical characteristics and CHADS2 score in patients with heart failure and atrial fibrillation: insights from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). [Int J Cardiol.](#) 176(1), 239-42, 2014 (IF=4.852)
12. **Fukushima A**, Kinugawa S, Takada S, Matsushima S, Sobirin MA, Ono T, Takahashi M, Suga T, Homma T, Masaki Y, Furihata T, Kadoguchi T, Yokota T, Okita K, Tsutsui H.: (Pro)renin receptor in skeletal muscle is involved in the development of insulin resistance associated with postinfarct heart failure in mice. [Am J Physiol Endocrinol Metab.](#) 307(6), E503-14, 2014 (IF=4.248)
13. Hirabayashi K, Kinugawa S, Yokota T, Takada S, **Fukushima A**, Suga T, Takahashi M, Ono T, Morita N, Omokawa M, Harada K, Oyama-Manabe N, Shirato H, Matsushima S, Okita K, Tsutsui H.: Intramyocellular lipid is increased in the skeletal muscle of patients with dilated cardiomyopathy with lowered exercise capacity. [Int J Cardiol.](#) 176(3):1110-2, 2014 (IF=4.852)
14. Sankaralingam S, Abo Alrob O, Zhang L, Jaswal JS, Wagg CS, **Fukushima A**, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD.: Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. [Diabetes.](#) 64(5), 1643-57, 2015 (IF=8.624)
15. Kadoguchi T, Kinugawa S, Takada S, **Fukushima A**, Furihata T, Homma T, Masaki Y, Mizushima W, Nishikawa M, Takahashi M, Yokota T, Matsushima S, Okita K, Tsutsui H.: Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. [Exp Physiol.](#) 100(3), 312-22, 2015 (IF=2.937)
16. **Fukushima A**, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Takada S, Kadoguchi T, Oba K, Okita K, Tsutsui H.: Serum brain-derived neurotrophic factor level predicts adverse clinical outcomes in patients with heart failure. [J Card Fail.](#) 21(4), 300-6, 2015 (IF=3.770)
17. Nishikawa M, Ishimori N, Takada S, Saito A, Kadoguchi T, Furihata T, **Fukushima A**, Matsushima S, Yokota T, Kinugawa S, Tsutsui H. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress. [Nephrol Dial Transplant.](#) 30(6), 934-42, 2015 (IF=3.938)
18. Lam VH, Zhang L, Huqi A, **Fukushima A**, Tanner BA, Onay-Besikci A, Keung W, Kantor PF, Jaswal JS, Rebeyka IM, Lopaschuk GD. Activating PPAR α prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. [Circ Res.](#) 117(1), 41-51, 2015 (IF=11.972)
19. Takada S, Kinugawa S, Matsushima S, Takemoto D, Furihata T, Mizushima W, **Fukushima A**, Yokota T, Ono Y, Shibata H, Okita K, Tsutsui H. Sesamin prevents decline in exercise capacity and impairment of skeletal muscle mitochondrial function in mice with high-fat diet-induced diabetes. [Exp Physiol.](#) 100(11), 1319-30, 2015 (IF=2.937)
20. Furihata T, Kinugawa S, Takada S, **Fukushima A**, Takahashi M, Homma T, Masaki Y, Tsuda M, Matsumoto J, Mizushima W, Matsushima S, Yokota T, Tsutsui H. The experimental model of transition from compensated cardiac hypertrophy to failure created by transverse aortic constriction in mice. [Int J Cardiol Heart Vasc.](#) 11, 24-28, 2016 (IF=0.519)
21. **Fukushima A**, Kinugawa S, Takada S, Matsumoto J, Furihata T, Mizushima W, Tsuda M, Yokota T, Matsushima S, Okita K, Tsutsui H. Direct renin inhibitor ameliorates insulin resistance by improving insulin signaling and oxidative stress in the skeletal muscle from post-infarct heart failure in mice. [Eur J Pharmacol.](#) 779, 147-56, 2016 (IF=2.730)
22. Ussher JR, Fillmore N, Keung W, Zhang L, Mori J, Sidhu VK, **Fukushima A**, Gopal K, Lopaschuk DG, Wagg CS, Jaswal

- JS, Dyck JR, Lopaschuk GD. Genetic and Pharmacological Inhibition of Malonyl CoA Decarboxylase Does Not Exacerbate Age-Related Insulin Resistance in Mice. [Diabetes. 65\(7\), 1883-91, 2016](#) (IF=8.624)
23. **Fukushima A**, Alrob OA, Zhang L, Wagg CS, Altamimi T, Rawat S, Rebeyka IM, Kantor PF, Lopaschuk GD. Acetylation and succinylation contribute to maturational alterations in energy metabolism in the newborn heart. [Am J Physiol Heart Circ Physiol. 311\(2\), H347-63, 2016](#) (IF=3.567)
24. Furihata T, Kinugawa S, **Fukushima A**, Takada S, Homma T, Masaki Y, Abe T, Yokota T, Oba K, Okita K, Tsutsui H. Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. [Int J Cardiol. 220, 483-7, 2016](#) (IF=4.852)
25. Takada S, Masaki Y, Kinugawa S, Matsumoto J, Furihata T, Mizushima W, Kadoguchi T, **Fukushima A**, Homma T, Takahashi M, Harashima S, Matsushima S, Yokota T, Tanaka S, Okita K, Tsutsui H. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. [Cardiovasc Res. 111\(4\), 338-47, 2016](#) (IF=5.833)
26. Yokota T, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, Kadoguchi T, Takahashi M, **Fukushima A**, Matsushima S, Yamato M, Okita K, Tsutsui H. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. [J Diabetes Investig. 8\(4\), 535-541, 2017](#) (IF=2.913)
27. Fillmore N, Levasseur J, **Fukushima A**, Wagg C, Wang W, Dyck J, Lopaschuk GD. : Uncoupling of Glycolysis from Glucose Oxidation Accompanies the Development of Heart Failure with Preserved Ejection Fraction. [Mol Med. Mar 15:24\(1\), 2018](#) (IF=4.304)
28. Fillmore N, Wagg CS, Zhang L, **Fukushima A**, and Lopaschuk GD. Cardiac branched-chain amino acid oxidation is reduced during insulin resistance in the heart. [Am J Physiol Endocrinol Metab 315: E1046-E1052, 2018.](#) (IF=4.125)
29. Kadoguchi T, Takada S, Yokota T, Furihata T, Matsumoto J, Tsuda M, Mizushima W, **Fukushima A**, Okita K, and Kinugawa S. Deletion of NAD(P)H Oxidase 2 Prevents Angiotensin II-Induced Skeletal Muscle Atrophy. [BioMed research international 3194917, 2018.](#) (IF=2.583)
30. Sakamoto M, Fukuda H, Kim J, Ide T, Kinugawa S, **Fukushima A**, Tsutsui H, Ishii A, Ito S, Asanuma H, Asakura M, Washio T, and Kitakaze M. The impact of creating mathematical formula to predict cardiovascular events in patients with heart failure. [Scientific reports 8: 3986, 2018.](#) (IF=4.122)
31. **Fukushima A**, Zhang L, Huqi A, Lam VH, Rawat S, Altamimi T, Wagg CS, Dhaliwal KK, Hornberger LK, Kantor PF, Rebeyka IM, and Lopaschuk GD. Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. [JCI insight May 17:3\(10\), 2018.](#) (IF=6.014)
32. Fukuda H, Shindo K, Sakamoto M, Ide T, Kinugawa S, **Fukushima A**, Tsutsui H, Ito S, Ishii A, Washio T, and Kitakaze M. Elucidation of the Strongest Predictors of Cardiovascular Events in Patients with Heart Failure. [EBioMedicine Jul:33:185-195, 2018.](#) (IF=6.680)
33. Yokota T, **Fukushima A**, Kinugawa S, Okumura T, Murohara T, and Tsutsui H. Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF). [International heart journal 59: 976-982, 2018.](#) (IF=1.826)
34. Tsuda M, **Fukushima A**, Matsumoto J, Takada S, Kakutani N, Nambu H, Yamanashi K, Furihata T, Yokota H, Okita K, Kinugawa S, Anzai T. Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure. [Journal of cachexia, sarcopenia and muscle Oct:9\(5\):844-859, 2018.](#) (IF=12.51)

35. Kakutani N, **Fukushima A**, Yokota T, Katayama T, Nambu H, Shirakawa R, Maekawa S, Abe T, Takada S, Furihata T, Ono K, Okita K, Kinugawa S, Anzai T. Impact of High Respiratory Exchange Ratio During Submaximal Exercise on Adverse Clinical Outcomes in Patients with Heart Failure. [Circ J Oct 25;82\(11\):2753-2760, 2018. \(IF=4.1\)](#)
36. Matsumoto J, Takada S, Kinugawa S, Furihata T, Nambu H, Kakutani N, Tsuda M, **Fukushima A**, Yokota T, Tanaka S, Takahashi H, Watanabe M, Hatakeyama S, Matsumoto M, Nakayama KI, Otsuka Y, Sabe H, Tsutsui H, and Anzai T. Brain-Derived Neurotrophic Factor Improves Limited Exercise Capacity in Mice With Heart Failure. [Circulation 138: 2064-2066, 2018. \(IF=23.05\)](#)
37. Omote K, Nagai T, Asakawa N, Kamiya K, Tokuda Y, Aikawa T, **Fukushima A**, Noguchi K, Kato Y, Komoriyama H, Nishida M, Kudo Y, Iwano H, Yokota T, and Anzai T. Impact of admission liver stiffness on long-term clinical outcomes in patients with acute decompensated heart failure. [Heart Vessels 34: 984-991, 2019. \(IF=1.62\)](#)
38. Altamimi TR, Karwi QG, Uddin GM, **Fukushima A**, Kwong JQ, Molkentin JD, and Lopaschuk GD. Cardiac-specific deficiency of the mitochondrial calcium uniporter augments fatty acid oxidation and functional reserve. [J Mol Cell Cardiol 127: 223-231, 2019. \(IF=5.055\)](#)
39. Tsujinaga S, Iwano H, Sarashina M, Hayashi T, Murayama M, Ichikawa A, Nakabachi M, Nishino H, Yokoyama S, **Fukushima A**, Yokota T, Okada K, Kaga S, Vlachos PP, and Anzai T. Diastolic Intra-Left Ventricular Pressure Difference During Exercise: Strong Determinant and Predictor of Exercise Capacity in Patients With Heart Failure. [J Card Fail 25: 268-277, 2019. \(IF=3.942\)](#)
40. Nakajima T, Yokota T, Shingu Y, Yamada A, Iba Y, Ujihira K, Wakasa S, Ooka T, Takada S, Shirakawa R, Katayama T, Furihata T, **Fukushima A**, Matsuoka R, Nishihara H, Dela F, Nakanishi K, Matsui Y, and Kinugawa S. Impaired mitochondrial oxidative phosphorylation capacity in epicardial adipose tissue is associated with decreased concentration of adiponectin and severity of coronary atherosclerosis. [Scientific reports 9: 3535, 2019. \(IF=4.122\)](#)
41. Altamimi TR, Gao S, Karwi QG, **Fukushima A**, Rawat S, Wagg CS, Zhang L, and Lopaschuk GD. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. [Metabolism 98: 37-48, 2019. \(IF=6.513\)](#)
42. Uddin GM, Zhang L, Shah S, **Fukushima A**, Wagg CS, Gopal K, Al Batran R, Pherwani S, Ho KL, Boisvenue J, Karwi QG, Altamimi T, Wishart DS, Dyck JRB, Ussher JR, Oudit GY, and Lopaschuk GD. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. [Cardiovasc Diabetol 18: 86, 2019. \(IF=5.948\)](#)
43. Wang W, Zhang L, Battiprolu PK, **Fukushima A**, Nguyen K, Milner K, Gupta A, Altamimi T, Byrne N, Mori J, Alrob OA, Wagg C, Fillmore N, Wang SH, Liu DM, Fu A, Lu JY, Chaves M, Motani A, Ussher JR, Reagan JD, Dyck JRB, and Lopaschuk GD. Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction. [JACC Basic Transl Sci 4: 385-400, 2019. \(IF, not determined\)](#)
44. Katayama T, Kinugawa S, Takada S, Furihata T, **Fukushima A**, Yokota T, Anzai T, Hibino M, Harashima H, and Yamada Y. A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells. [Mitochondrion 49: 66-72, 2019. \(IF=3.449\)](#)
45. Nakano I, Hori H, **Fukushima A**, Yokota T, Kinugawa S, Takada S, Yamanashi K, Obata Y, Kitaura Y, Kakutani N, Abe T, and Anzai T. Enhanced Echo Intensity of Skeletal Muscle Is Associated With Exercise Intolerance in Patients With Heart Failure. [J Card Fail. 2019. \(IF=3.942\)](#)
46. Shirakawa R, Yokota T, Nakajima T, Takada S, Yamane M, Furihata T, Maekawa S, Nambu H, Katayama T, **Fukushima A**, Saito A, Ishimori N, Dela F, Kinugawa S, and Anzai T. Mitochondrial reactive oxygen species generation in blood cells

is associated with disease severity and exercise intolerance in heart failure patients. [Scientific reports 9: 14709, 2019.](#)

(IF=4.122)

47. Nambu H, Takada S, **Fukushima A**, Matsumoto J, Kakutani N, Maekawa S, Shirakawa R, Nakano I, Furihata T, Katayama T, Yamanashi K, Obata Y, Saito A, Yokota T, and Kinugawa S. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. [Eur J Pharmacol 866: 172810, 2020.](#) (IF=3.170)
48. Maekawa S, Takada S, Furihata T, **Fukushima A**, Yokota T, and Kinugawa S. Mitochondrial respiration of complex II is not lower than that of complex I in mouse skeletal muscle. [Biochem Biophys Rep 21: 100717, 2020.](#) (IF, not determined)
49. Nakano I, Kinugawa S, Hori H, **Fukushima A**, Yokota T, Takada S, Kakutani N, Obata Y, Yamanashi K, and Anzai T. Serum Brain-Derived Neurotrophic Factor Levels Are Associated with Skeletal Muscle Function but Not with Muscle Mass in Patients with Heart Failure. [International heart journal, 2020.](#) (IF=1.826)
50. Takahashi M, Kinugawa S, Takada S, Kakutani N, Furihata T, Sobirin MA, **Fukushima A**, Obata Y, Saito A, Ishimori N, Iwabuchi K, and Tsutsui H. The disruption of invariant natural killer T cells exacerbates cardiac hypertrophy and failure due to pressure overload in mice. [Exp Physiol, 2020.](#) (IF=2.624)

II 総説 (英文)

1. **Fukushima A**, Lopaschuk GD: Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets. [Curr Pharm Des. 21, 3654-3664, 2015](#)
2. **Fukushima A**, Lopaschuk GD: Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. [Biochim Biophys Acta. 1860, 1525-1534, 2016](#)
3. **Fukushima A**, Lopaschuk GD: Acetylation control of cardiac fatty acid beta-oxidation and energy metabolism in obesity, diabetes, and heart failure. [Biochim Biophys Acta. 1862, 2211-2220, 2016](#)

III 症例報告 (英文)

1. Kato Y, **Fukushima A**, Iwano H, Kamiya K, Nagai T, and Anzai T. A case of medical management of tricuspid regurgitation related to atrial fibrillation with constrictive pericarditis-like hemodynamics. [J Cardiol Cases 18: 175-179, 2018.](#)
2. Hagiwara H, **Fukushima A**, Iwano H, and Anzai T. Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: a case report. [Eur Heart J Case Rep 2: yty100, 2018.](#)
3. Komoriyama H, **Fukushima A**, Takahashi Y, Kinugawa S, Sera F, Ohtani T, Nakamura A, Sakata Y, and Anzai T. Rapidly Progressive Heart Failure in a Female Carrier of Becker Muscular Dystrophy with No Skeletal Muscle Symptoms. [Intern Med 58: 2545-2549, 2019.](#)
4. Takahashi Y, Iwano H, Nakano I, **Fukushima A**, Naya M, Shimizu A, Matsuno Y, Oyama-Manabe N, and Anzai T. POEMS Syndrome Showing Left Ventricular Dysfunction and Extracellular Edema Assessed by Cardiac Magnetic Resonance Imaging. [Intern Med 58: 2539-2543, 2019.](#)

III その他 (Editorial)

1. **Fukushima A**, and Kinugawa S. Renin-Angiotensin-Aldosterone System and Natriuretic Peptides as Possible Targets of Waon Therapy in Heart Failure. *Circ J* 81: 635-636, 2017.
2. **Fukushima A**, and Kinugawa S. Hyponatremia as a surrogate marker for optimal diuretic selection in acute heart failure. *J Cardiol* 71: 547-549, 2018.
3. Kinugawa S and **Fukushima A**. Malnutrition in Heart Failure: Important But Undervalued Issue. *JACC Heart failure* 6: 487-488, 2018.
4. Kinugawa S and **Fukushima A**. First Hospitalization Tells Us Everything About Heart Failure. *Circ J* 83: 1200-1201, 2019.

IV 著書 (和文)

(1) 単著

1. **福島 新**: さまざまな心不全の病態に対する心臓リハビリテーション サルコペニアを合併した心不全, 89頁-93頁 (包括的心臓リハビリテーションを極める 絹川真太郎編, 文光堂, 東京), 2016
2. **福島 新**: I章-2. 原因不明の心肥大・収縮障害を認めたら (実は知らない循環器希少疾患 安斉 俊久編, 南江堂, 東京), 2019
3. **福島 新**: II-6. 心臓リハビリテーション (重症心不全治療プラクティス 安斉 俊久編, 南江堂, 東京), 2019
4. **福島 新**: IV章-case study12: 末期心不全をきたした高齢拡張型心筋症のケース (重症心不全治療プラクティス 安斉 俊久編, 南江堂, 東京), 2019

(2) 共著

1. **福島 新**, 筒井 裕之: 心筋梗塞後心不全のインスリン抵抗性におけるプロレニン-(プロ)レニン受容体の役割, (Angiotensin Research, 先端医学社, 東京), 2015
2. 絹川 真太郎, **福島 新**: 体重が減っています。筋肉が減少していませんか? 151頁-156頁 (エキスパートが現場で明かす 心不全診療の極意, 佐藤幸人編, 南山堂, 東京), 2016
3. **福島 新**, 絹川 真太郎: 虚血性心疾患による心不全のメカニズム, 74頁-76頁 (日本医事新報, 東京), 2016
4. **福島 新**, 高田 真吾: VII.診断 血液生化学 マイオカイ, 日本臨牀2018年12月増刊「心不全 (第2版) 上巻-最新の基礎・臨床研究の進歩」, 2018

VI 主な受賞歴:

1. 平成25年 Abstract Travel Award at 'XXI International Society for Heart Research World Congress', California, USA.
2. Finalist of Young Investigator Award, 第19回日本心臓リハビリテーション学会学術集会, 仙台
3. 平成26年 公益財団法人鈴木万平糖尿病財団 海外留学助成金
4. 平成26年 持田記念海外留学補助金
5. 平成29年 文部科学省科学研究費基盤研究 (C) (一般: 平成29年-31年、代表)
6. 公益財団法人笹川記念保健協力財団 ホスピス緩和ケアに関する研究助成金
7. 公益財団法人石本記念デサントスポーツ科学振興財団学術研究
8. 金原一郎記念医学医療振興財団 研究交流助成金
9. 公益財団法人武田科学振興財団 医学系研究奨励
10. 公益財団法人宮田心臓病研究振興基金 未成年心臓血管病助成金

11. 第37回 高桑榮松奨学基金奨励賞